

PAQFLOR™ (Florfenicol) Veterinary Feed Directive

Address: Phone: Phone:	Client:			Veterinarian:				
Phone: Phone:	Home or			Address				
proximate Number: nimal Location: **Rich Species*** Indication*** First Species** Indication** For the control of mortality due to funuculoss accounted with Announced International Section of the Control of mortality due to funuculoss accounted with Announced International Section of Inter	susiness Address:			Address:				
procrimate Number: Initial Location: Indications: Circle the row with the breated species and indication, and initial the corresponding box. Final Species Indication Floriferical (grammation) Initials (grammation)	Dhono			Dhonoi				
Initial Locations: Indications: Circle the row with the treated species and indication, and initial the corresponding box. Fish Species Indication	'none:		rnone:					
Firsh Species Indications Indication I	Approximate Number:							
Find Species indication (mg/kg body weight/day) (Florfenicol (gramstron) (Initials associated with Accordance sanociated with Revealed sanociated with Stepandociated sanociated with Stepandociated stealure. Secondance sanociated with Stepandociated stealure sanociated with Stepandociated with Stepandociated stealure sanociated with Stepandociated with Stepandociated specific stealure sanociated with Stepandociated with Stepandociated specific stealure sanociated with Stepandociated with Stepandociated specific stealure sanociated stealure sanociated stealure sanociated with Stepandociated specific stealure sanociated stealure sanocia	Animal Location:							
Freshwater-reared salmonids Freshwater-reared salmonids Freshwater-reared salmonids Freshwater-reared salmonids Freshwater-reared finifish Freshwater-reared finifish Freshwater-reared finifish Freshwater-reared finifish Freshwater-reared salmonids Freshwater-reared salmonids Freshwater-reared salmonids Freshwater-reared warmwater Freshw	ndications: Circle the row wit	th the treated species	and indication, an	d initial the cor	responding box.			
Freshwater record salmonids For the control of mortality due to activate disease associated with Announces somenations. For the control of mortality due to activate disease associated with Freshwater record finds associated with Freshwater in activation of a state of the Control of mortality due to activate disease associated with Freshwater in activate in a state of the Control of mortality due to activate disease and the Control of the Control of mortality due to activate disease and the Control of the Control of mortality due to activate disease and the Control of the Control of mortality due to activate disease. For the control of mortality due to activate disease and the Control of the Control of mortality due to activate disease. Freshwater-revered warmwater from the control of mortality due to activate disease. Freshwater-revered warmwater fresh associated with Streptococcus iniae. Freshwater-reversed fresh before provided to the fresh associated with streptococcus iniae. Freshwater-reversed fresh before provided to the Streptococcus iniae. Freshwater-reversed fresh before provided fresh associated with Streptococcus iniae. Freshwater-reversed fresh before provided fresh associated with Streptococcus iniae.	Fish Species		Indication					Initials
Freshwater reard finish Freshwater reard finish Freshwater reard finish Freshwater reard finish Freshwater reard warmwater Freshwater-reard finish Freshwater-reard warmwater Freshwater-reard warmwater Freshwater-reard finish Freshwater-reard warmwater Freshwater-reard finish Freshwater-reard warmwater Freshwater-reard warmwa	Freshwater-reared salmonids	associated with Aeromonas salmonicida. For the control of mortality due to coldwater disease						
Collision of catifish associated with Edwardsiella Ictalum. Freehwater-reared warmwater fundion Freeding Rate:	Freshwater-reared finfish	For the control of mortality due to columnaris disease			10 –15		182 - 2,724	
ix into Type C Medicated Feed to Provide:	Catfish		,					
Feeding Rate					15		273 - 2,724	
reding Rate:				(0	,	-		
Feeding Rate Florenical Concentration in Feed Romant of PAQFLOR (tortenact) per Ton of Feed Feed per 10-day Treatment Period			•	(See table below	.)			
Feeding Rate Florencol Concentration in Feed (thorfenicol) per Ton of Feed Feed per 10-day Treatment Period	eeding Duration: Feed as the sole	e ration for 10 consecution	ve days.					
Section Does 10 mg/kg Does 15 mg/kg Does 15 mg/kg Does 15 mg/kg Does 15 mg/kg	Feeding Rate	Florfenicol Concentration in Feed						
Dose 16 mg/kg Dose 10 mg/kg Dose 16 mg/kg Dose 16 mg/kg Dose 10 mg/kg Dose 16 mg/kg Dose 10 mg/kg Dose		Grams/Ton		(nonono				it i chou
1.0 908 1,362 4.00 6.00 20,000 2.0 454 681 2.00 3.00 10,000 3.0 300 450 1.32 1.98 6.668 5.0 182 273 0.80 1.20 4,000 gecial instructions: e of feed containing this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling (extralabel use) is not permitted. is VFD only authorizes the use of the VFD drug cited in this order and is not intended to authorize the use of such drug in combination with any other animal drugs. ution: Feed containing PAGFLOR™ (florenco) shall not be fed to fish for more than 10 days. Following 10 days administration, fish should be reevaluated by a licensed veterinarian befinding another course of therapy. The expiration date for VFD PAGFLOR (florenco) must not exceed 6 months from the date of issuance. VFD for PAGFLOR (florenco) shall not be reflicted an animals intended for breeding purposes. The effects of florencod or reproductive performance have not been determined. Toxicity studies in dogs, rats, and mice have associated of the formation with testicular degeneration and attoryth. For catilish, a dose-related decrease in hematopoietic/lymphopoietic issues may occur. The time required for the hematopoieti phipopoietic issues to regenerate was not evaluated. Into missions, and skin sloughing have been reported in salmonids treated with florenciol. Not all adverse drug events are reported to FDA CVIM. It is not always possible to reliably imited the adverse event incidence or to establish a causal reliablonship to product exposure using this data alone. Into using this drug for the first time, you must inform the appropriate National Pollutari Discharge Elimination System (NPDES) permitting authority of your intentions and of the following time to the Great Lakes System (40 CFR 132, App. A.). The acute benchmark value (Secondary Oncident) for florencio following EFA guidance for calculating Tier II ter quality criteria for the Great Lakes System (40 CFR 132, App. A.). The acute benchmark value (Secondary Combined to the NPDES authority by cquidance f	% Biomass	Dose 10 mg/kg	Dose 15 mg/kg	Dose 10 mg/kg	Dose 15 mg/kg			
2.0	0.5	1,816	2,724	8.00	12.00		40,000	
3.0 300 450 182 273 0.80 1.32 1.98 6.6666 5.0 182 273 0.80 1.20 4,000 pecial Instructions: are of feed containing this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling (extralabel use) is not permitted. syFD only authorizes the use of the VFD drug cited in this order and is not intended to authorize the use of such drug in combination with any other animal drugs. sufficiency of the properties of th							· · · · · · · · · · · · · · · · · · ·	
pecial Instructions: be of feed containing this veterinary feed directive (VFP) drug in a manner other than as directed on the labeling (extralabel use) is not permitted. s VFD only authorizes the use of the VFD drug cited in this order and is not intended to authorize the use of such drug in combination with any other animal drugs. ution: Feed containing PAQFLOR™ (florfenicol) shall not be fed to fish for more than 10 days. Following 10 days administration, fish should be reevaluated by a licensed veterinarian befunding another course of therapy. The expiration date for VFD PAQFLOR (florfenicol) must not exceed 6 months from the date of issuance. VFD for PAQFLOR (florfenicol) shall not be reflict this an animals intended for breeding purposes. The effects of florfenicol on reproductive performance have not been determined. Toxicity studies in dogs, rats, and nice have sue of florfenicol with testicular degeneration and atrophy. For caffish, a dose-related decrease in hematopoietic/hymphopoietic tissue may occur. The time required for the hematopoietic phopoietic tissues to regenerate was not evaluated. hourn, skin lesions, and skin skoughing have been reported in salmonids treated with florfenicol. Not all adverse drug events are reported to FDA CVM. It is not always possible to reliably intended the diverse drug events are reported to FDA CVM. It is not always possible to reliably intended to diverse drug events are reported to FDA CVM. It is not always possible to reliably intended to diverse drug events are reported to FDA CVM. It is not always possible to reliably mantate the adverse event incidence or to establish a causal relationship to product exposure using this data alone. For using this drug for the first time, you must inform the appropriate National Pollutant Discharge Elimination System (NPDES) permitting authority of your intentions and of the following propriate to the following the first time, you must inform the appropriate National Pollutant Discharge Elimination System (NPDES) permitti							· · · · · · · · · · · · · · · · · · ·	
e of feed containing this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling (extralabel use) is not permitted. is VFD only authorizes the use of the VFD drug cited in this order and is not intended to authorize the use of such drug in combination with any other animal drugs. ution: Feed containing PAQFLOR™ (florfenicol) shall not be fed to fish for more than 10 days. Following 10 days administration, fish should be reevaluated by a licensed veterinarian befuring another course of therapy. The expiration date for VFD PAQFLOR (florfenicol) must not exceed 6 months from the date of issuance. VFD for PAQFLOR (florfenicol) shall not be refit to ruse in animals intended for breeding purposes. The effects of florfenicol on reproductive performance have not been determined. Toxicity studies in dogs, rats, and mice have associate use of florfenicol with testicular degeneration and atrophy. For catfish, a dose-related decrease in hematopoietic/lymphopoietic tissue may occur. The time required for the hematopoieting purpose to regenerate was not evaluated. Inburn, skin lesions, and skin sloughing have been reported in salmonids treated with florfenicol. Not all adverse drug events are reported to FDA CVM. It is not always possible to reliably imate the adverse event incidence or to establish a causal relationship to product exposure using this data alone. fore using this drug for the first time, you must inform the appropriate National Pollutant Discharge Elimination System (NPDES) permitting authority of your intentions and of the following material and chronic vater quality benchmarks for the protection of freshwater aquality life have been derived by FDA for forfericio following EPA guidance for calculating Tier II ter quality orities for the Great Lakes System (40 CFR 132, App. A). The acute benchmark value (Secondary for forfericion for life fresh and chronic vater quality benchmarks for the permit. Advironmental information in PAQFLOR. The water quality benchmark concentrati							*	
e of feed containing this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling (extralabel use) is not permitted. s VFD only authorizes the use of the VFD drug cited in this order and is not intended to authorize the use of such drug in combination with any other animal drugs. ution: Feed containing PAGFLOR™ (florfenicol) shall not be fed to fish for more than 10 days. Following 10 days administration, fish should be reevaluated by a licensed veterinarian befring another course of therapy. The expiration date for VFD PAGFLOR (florfenicol) must not exceed 6 months from the date of issuance. VFD for PAGFLOR (florfenicol) shall not be reflict or use in animals intended for breeding purposes. The effects of florfenicol on reproductive performance have not been determined. Toxicity studies in dogs, rats, and mice have assoce use of florfenicol with testicular degeneration and atrophy. For catlish, a dose-related decrease in hematopoieticilymphopoietic tissue may occur. The time required for the hematopoietiphopoietic loss to regenerate was not evaluated. nburn, skin lesions, and skin sloughing have been reported in salmonids treated with florfenicol. Not all adverse drug events are reported to FDA CVM. It is not always possible to reliably imate the adverse event incidence or to establish a causal relationship to product exposure using this drug for the first time, you must inform the appropriate National Pollutaria Discharge Elimination System (NPDES) permitting authority or your intentions and of the following row using this drug for the first time, you must inform the appropriate National Pollutaria Discharge Elimination System (NPDES) permitting authority or your intentions and of the following row using the production of freshwater aquality life have been derived by FDA for florfenicol following EPA guidance for calculating Tier II let quality criteria for the Great Lakes System (40 CFR 132, App. A). The acute benchmark value (Secondary Maximum Concentration) is 20 fi mg/L	5.0	182	2/3	0.80	1.20		4,000	
month/day/year (Not to exceed 6 months from issuance date) eterinarian's Signature: Date of Issuance (Month/Day/Year):	is VFD only authorizes the use of the Vertical States of the Vertical States of the Vertical States of the Indiana States of the Indiana States of the Indiana States of the Indiana States of Indiana Indiana States of Indiana States of Indiana India	/FD drug cited in this order orfenicol) shall not be fed to expiration date for VFD PAQ in properties. The effects of the effe	and is not intended to a fish for more than 10 d FLOR (florfenicol) must florfenicol on reproductifish, a dose-related demonids treated with florfenship to product exposu ate National Pollutant Dection of freshwater aqual. The acute benchma Concentration) is 0.23 is concentrations are not defined to a fish for the concentrations are not defined to a fish for the concentrations are not defined to a fish for the concentrations are not defined to a fish fish for the concentrations are not defined to a fish fish for the concentrations are not defined to a fish fish fish for the concentration and the concentrations are not defined to a fish fish fish fish fish fish fish fish	uthorize the use of ays. Following 10 c not exceed 6 month tive performance hacrease in hematopolenicol. Not all advere using this data a ischarge Eliminatio uatic life have been rk value (Secondarmg/L (equivalent to ischarge limits, but	such drug in combination vays administration, fish shots from the date of issuance ave not been determined. To itelic/lymphopoietic tissue rates drug events are reported lone. In System (NPDES) permitted derived by FDA for florfenity Maximum Concentration) the Final Plant Value). The may be used by the NPDE	vith any ot puld be rece. VFD for coxicity stumay occur and to FDA comments of the following author col following author to S authorities S authorities of the comments of the following authorities of the following autho	her animal drugs. evaluated by a licensed PAQFLOR (florfenicol dies in dogs, rats, and . The time required for CVM. It is not always partity of your intentions and EPA guidance for cog/L (equivalent to one-authority may require a y to derive such limits.	nice have associ the hematopoietic possible to reliably and of the following alculating Tier II half of the Second in NPDES permit for the permit. Add
eterinarian's Signature: Date of Issuance (Month/Day/Year):		RESIDUE WARNING: Fe	eds containing PAQFLC	PR (florfenicol) must	be withdrawn 15 days prio	or to slaugl	nter.	
	FD Expiration Date:			mon	th/day/year (Not to exceed 6 m	onths from	issuance date)	
☐ DRUG PRODUCT SUBSTITUTION IS NOT ALLOWED.	eterinarian's Signature:				Date of Issua	ance (Mon	th/Day/Year):	
	DRUG PRODUCT SUBSTITU	ITION IS NOT ALLOW	ED.					

PF063624USA Rev. August, 20, 2024